{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:53:05Z","timestamp":1782395585509,"version":"3.54.5"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Jejunal carcinoma is an exceptionally rare malignancy with limited therapeutic options beyond chemotherapy. Polymerase epsilon (POLE) mutations in this tumor type are even rarer, yet they may represent a predictive biomarker for response to immune checkpoint inhibitors in jejunal cancer and agnostically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 58-year-old male patient diagnosed with a POLE-mutated jejunal carcinoma. He presented with left-sided abdominal pain and was found to have an extremely large mass in the left upper quadrant. Biopsy confirmed jejunal adenocarcinoma. He was initially treated with two cycles of FOLFOX, and upon detection of the POLE mutation, nivolumab was added. After four cycles of chemo-immunotherapy, imaging demonstrated significant tumor regression. However, radiologic and clinical signs of subocclusion prompted treatment discontinuation and surgical resection. Histopathologic analysis revealed a complete pathological response, with no viable tumor cells. The patient has been disease-free since January 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the role of immunotherapy in POLE-mutated tumors regardless of the site of origin and highlights the potential usefulness of molecular profiling in rare malignancies. In line with the agnostic approach used for microsatellite instability, molecular-driven clinical trials should be prioritized over histology-based studies to optimize treatment strategies for these orphan diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag223","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:46:59Z","timestamp":1780573619000},"source":"Crossref","is-referenced-by-count":0,"title":["Rarity within rarity: complete response to chemoimmunotherapy in a patient with polymerase epsilon (POLE)-mutated locally advanced jejunal carcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-469X","authenticated-orcid":false,"given":"Michele","family":"Prisciandaro","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-3596","authenticated-orcid":false,"given":"Federica","family":"Morano","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Citterio","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic, Upper GI and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Flores Reyes","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic, Upper GI and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Barella","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Innovation, Pathology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4013-8085","authenticated-orcid":false,"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"Hepatobiliary Pancreatic, Upper GI and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026062509363572400_oyag223-B1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci7030046","article-title":"Epidemiology of cancers of the small intestine: trends, risk factors, and prevention","volume":"7","author":"Barsouk","year":"2019","journal-title":"Medical Sciences (Basel, Switzerland)"},{"key":"2026062509363572400_oyag223-B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051137","article-title":"Therapeutic strategies for patients with advanced small bowel adenocarcinoma: current knowledge and perspectives","volume":"14","author":"Moati","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026062509363572400_oyag223-B3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat Genet"},{"key":"2026062509363572400_oyag223-B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2026062509363572400_oyag223-B5","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2026062509363572400_oyag223-B6","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 blockade in solid tumors with defects in polymerase epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov"},{"key":"2026062509363572400_oyag223-B7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients","volume":"101","author":"Dabaja","year":"2004","journal-title":"Cancer"},{"key":"2026062509363572400_oyag223-B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc.2015.12","article-title":"A panoply of errors: polymerase proofreading domain mutations in cancer","volume":"16","author":"Rayner","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026062509363572400_oyag223-B9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and Microsatellite-Instable endometrial cancers with neoantigen load, number of Tumor-Infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026062509363572400_oyag223-B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000881","article-title":"Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer","volume":"8","author":"Mo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062509363572400_oyag223-B11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"key":"2026062509363572400_oyag223-B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-024-01939-5","article-title":"A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon\/polymerase Delta (POLE\/POLD1) mutation","volume":"9","author":"Jin","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026062509363572400_oyag223-B13","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-Positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026062509363572400_oyag223-B14","doi-asserted-by":"publisher","first-page":"S463","DOI":"10.1016\/j.annonc.2020.08.640","article-title":"526O high activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated mismatch repair proficient (MMRp) advanced tumours","volume":"31","author":"Rousseau","year":"2020","journal-title":"Annals of Oncology"},{"key":"2026062509363572400_oyag223-B15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK Fusion-Positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062509363572400_oyag223-B16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026062509363572400_oyag223-B17","doi-asserted-by":"publisher","first-page":"103698","DOI":"10.1016\/j.esmoop.2024.103698","article-title":"Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series","volume":"9","author":"Platt","year":"2024","journal-title":"ESMO Open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag223\/68475741\/oyag223.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag223\/68475741\/oyag223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag223\/68475741\/oyag223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:36:42Z","timestamp":1782394602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag223\/8702460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag223","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,4]]},"article-number":"oyag223"}}